Www.ncbi.nlm.nih.gov



Evidence Table 21. KQ2StudyPatients includedPatient characteristicsComparatorsNumber of patientsStudy Design, Risk of biasOutcomesResultsCIGTS 2001 QUOTE "115 116" ADDIN PROCITE ?\11\05‘\19\02\00\00\00\07115 116\01\01\00\07\00\00\01\00\00\00\1BM_\01\00\00\008??\01H?v\01\01\00\00\00\01\00\00\00\00\00\00\008\00\00\00?\04\00\00;Y:\5CGlaucoma\5CDatabase\5CTreatment\5CDec 2\5CGlaucoma-Treatment.pdt\1DJanz, Wren, et al. 2007 #1253\00\1D\00 115 116 QUOTE "" ADDIN PROCITE ?\11\05‘\19\02\00\00\00\00\01\00\00o\0C\00\00;Y:\5CGlaucoma\5CDatabase\5CTreatment\5CDec 2\5CGlaucoma-Treatment.pdt\1DJanz, Wren, et al. 2001 #3179\00\1D\00 POAG, PXF, pigmentaryGlaucoma-age range 35-64-55% white, 38% black-mean vertical C/D ratio 0.69Trabeculectomy (with or without 5-fluorouracil), if treatment failed ALT, then sequence of medications, then repeating trabeculectomy with antifibrotic agents, then repeating medications vs.Medications, starting with topical beta-blocker followed by other topical agents (up to three), then alternative topical and/or oral medications. If treatment failed ALT, then trabeculectomy (with or without 5-fluorouracil), repeating medication, repeating trabeculectomy with antifibrotic agents, repeating medication607 patientsRCT1. Low2. low3. unclear4. low5. low-Visual Activities QuestionnaireGlaucoma (VAQ),- Symptom and health problem check list (frequency and bothersomeness)- Glaucoma Health Perceptions Index-Fear of blindness- Total VAQ: No statistically significant differences.On VAQ acuity subscale, adjusted for baseline variables, primary surgery was associated more dysfunction than initial medical treatment (p = 0.02).- Symptom and health problem check list : Overall decrease in both groups. 12 symptoms were more reported in the surgical group and 7 symptoms were more reported in the medical groupSurgical patients reporting 22% more symptom bothersomeness related to visual function-No statistically significant differences on the Glaucoma Health Perceptions Index-Fear of blindness decreased in both groups and was not associated with a specific treatmentJavitt2000 QUOTE "45" ADDIN PROCITE ?\11\05‘\19\02\00\00\00\0245\01\01\00\02\00\00\01\00\00\00\1BM_\00\00\00\00?—?\01?—?\01\01\00\00\008\00\00\00\00\00\00\008\00\00\00\06\0E\00\00;Y:\5CGlaucoma\5CDatabase\5CTreatment\5CDec 2\5CGlaucoma-Treatment.pdt\1DJavitt & Schiffman 2000 #3584\00\1D\00 45POAG, OHT-mean age 58-56% white, 39% blackBrimonidine tartrate 0.2% twice dailyvsTimolol maleate 0.05% twice dailyFor 4 months219 patientsRCT1. low2. low3. low4. high5. high-Short Form-36 Health Survey (SF-36)no statistically significant changes in QOLEMGT2005 QUOTE "36" ADDIN PROCITE ?\11\05‘\19\02\00\00\00\0236\01\01\00\02\00\00\01\00\00\00\1BM_\00\00\00\00??v\01H?v\01\01\00\00\008\00\00\00\00\00\00\008\00\00\00?\07\00\00;Y:\5CGlaucoma\5CDatabase\5CTreatment\5CDec 2\5CGlaucoma-Treatment.pdt"Hyman, Komaroff, et al. 2005 #1932\00"\00 36POAG, NTG, PXF-mean age 68-mean visual acuity 0.9No treatment vs.Betaxolol 5mg/ml twice daily and ALT, Latanoprost if IOP exceeds 25mmHg255 patientsRCT1. low2. low3. low4. high5. low-Swedish translation of the NEI VFQ-25Treatment was not associated with change in QOL.Konstas2003 QUOTE "52" ADDIN PROCITE ?\11\05‘\19\02\00\00\00\0252\01\01\00\02\00\00\01\00\00\00\1BM_\00\00\00\00??v\01?—?\01\01\00\00\008\00\00\00\00\00\00\008\00\00\00?\0A\00\00;Y:\5CGlaucoma\5CDatabase\5CTreatment\5CDec 2\5CGlaucoma-Treatment.pdt%Konstas, Kozobolis, et al. 2003 #2767\00%\00 52PXF with OHT, PXF-mean age 70-average visual acuity 20/40Latanoprost 0.005% once dailyvs.Timolol maleate/Dorzolamide fixed combination twice dailyEach for 2 months54 patientsRandomized cross-over trial1. unclear2. unclear3. low4. high5. unclear-Preference for one treatment arm80 % preferred lanatanoprost vs. 20% Timolol/Dorzolamide(mostly because of convenience)Schenker1999 QUOTE "81" ADDIN PROCITE ?\11\05‘\19\02\00\00\00\0281\01\01\00\02\00\00\01\00\00\00\1BM_\00\00\00\000è?\010??\01\01\00\00\008\00\00\00\00\00\00\008\00\00\00P\0F\00\00;Y:\5CGlaucoma\5CDatabase\5CTreatment\5CDec 2\5CGlaucoma-Treatment.pdt$Schenker, Maloney, et al. 1999 #3911\00$\00 81POAH and OHT-mean age 59-70 % white, 24% blackTimolol Gel once daily vs.Timolol Solution twice dailyEach for 6 weeks202 patientsRandomized cross-over trial1. unclear2. unclear3. low4. low5. high-Antiglaucoma patient-preference questionnaire(includes: satisfaction,compliance)-71% preferred timolol gel vs. 29% timolol solution (mostly because of frequency of usage)-there was no statistically significant difference for satisfaction-compliance was statistically significant higher with timolol gelSolish2004 QUOTE "89" ADDIN PROCITE ?\11\05‘\19\02\00\00\00\0289\01\01\00\02\00\00\01\00\00\00\1BM_\00\00\00\00hè?\01h??\01\01\00\00\008\00\00\00\00\00\00\008\00\00\00+\09\00\00;Y:\5CGlaucoma\5CDatabase\5CTreatment\5CDec 2\5CGlaucoma-Treatment.pdt"Solish, DeLucca, et al. 2004 #2344\00"\00 89POAG, OHT, PXF and pigmentaryGlaucoma-Mean age 64-65% white, 25% black-45% had visual field defects0.5% Timolol maleate/ 2% Dorzolamide fixed combination twice dailyvs0.5% Timolol maleate and 0.2% Brimonidine twice dailyFor 6 months492 patientsRCT1. unclear2. unclear3. low4. low5. high-Convenience -Satisfaction(On a 7 point scale)Both treatments were convenient for >80% of patients and satisfied > 82% of the patients. Dorzolamide/timolol fixed combination was better than Brimonidine+ Timolol, regarding convenience but this did not reach statistical significance.Simmons2002 QUOTE "117" ADDIN PROCITE ?\11\05‘\19\02\00\00\00\03117\01\01\00\03\00\00\01\00\00\00\1BM_\00\00\00\00?9\13\01°?\06\01\01\00\00\008\00\00\00\00\00\00\008\00\00\00+\0C\00\00;Y:\5CGlaucoma\5CDatabase\5CTreatment\5CDec 2\5CGlaucoma-Treatment.pdt\19Simmons & Earl 2002 #3111\00\19\00 117POAG, OHT, PXF-Mean age 65-66% white, 24% black0.2% Brimonidine VsLatanoprost 0.005%For 3 months115patientsRCT1. unclear2. unclear3. low4. low5. high-Glaucoma disability indexPatientsin the latanoprost group were more likely to report negative quality-of-life variables than patients in thebrimonidine groupCantor2001 QUOTE "118" ADDIN PROCITE ?\11\05‘\19\02\00\00\00\03118\01\01\00\03\00\00\01\00\00\00\1BM_\00\00\00\00?è?\01è?\06\01\01\00\00\008\00\00\00\00\00\00\008\00\00\00?\0C\00\00;Y:\5CGlaucoma\5CDatabase\5CTreatment\5CDec 2\5CGlaucoma-Treatment.pdt\1FCantor, Hoop, et al. 2001 #3261\00\1F\00 118POAG, OHT, PXF-Mean age 59-77% white, 17% blackBrimonidineVsBetaxololFor 1 month159patientsRCT1. unclear2. unclear3. low4. low5. high-Glaucoma disability indexMean scores on theGDI did not change significantly frombaseline in either treatment group,Javitt2000 QUOTE "119" ADDIN PROCITE ?\11\05‘\19\02\00\00\00\03119\01\01\00\03\00\00\01\00\00\00\1BM_\00\00\00\00\10é?\01 ?\06\01\01\00\00\008\00\00\00\00\00\00\008\00\00\00?\0D\00\00;Y:\5CGlaucoma\5CDatabase\5CTreatment\5CDec 2\5CGlaucoma-Treatment.pdt\1CJavitt & Goldberg 2000 #3498\00\1C\00 119POAG, OHT-Mean age 61-82% white, 15% blackBrimonidineVsBetaxololFor 4 months188 patientsRCT1. low2. unclear3. low4. low5. high-Glaucoma disability indexThere were no significant between-group differences in the incidence ofadverse events or in the quality of life summary scores.Abbreviations: PXF= Pseudoexfoliative Glaucoma; NTG= Normal tension Glaucoma; ALT=Argon Laser Trabeculoplasty; NEI VFQ-25= National Eye Institute Visual Function Questionnaire. Risk of Bias: 1. Sequence Generation 2.Allocation Concealment 3.Blinding of Participants, Personnel, and Outcome Assessors 4.Incomplete Outcome Data 5.Pharmaceutical Support ................
................

In order to avoid copyright disputes, this page is only a partial summary.

Google Online Preview   Download